Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban to prevent early worsening of alcohol-related cirrhosis
ISRCTN11391276Phase 3Recruiting
- Sponsor
- University College London
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis, alcoholic liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Apixaban with Placebo (2 arms). Started Jun 2026; status: recruiting.
02
Drugs
apixaban
03
Conditions
Cirrhosisalcoholic liver disease (ALD)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ISRCTN11391276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11391276.